U.S. court rejects Alvogen’s patent challenge for Celgene’s cancer drug

49

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp’s blockbuster myeloma drug Revlimid.

http://feeds.reuters.com/~r/reuters/healthNews/~3/W3x0WDwYCB0/u-s-court-rejects-alvogens-patent-challenge-for-celgenes-cancer-drug-idUSKCN1QV1VD